Product description

MyoKi offers a novel, peptide-based solution that counteracts this effect by selectively inhibiting myostatin, a key regulator of muscle atrophy. MyoKi’s convenient oral formulation makes it an ideal adjunct therapy to GLP-1 treatments, helping preserve functional muscle mass and mobility. Its efficacy has been validated across genders and age groups, and it holds promise for broader applications.
Read more

Products from other suppliers